144 related articles for article (PubMed ID: 35612493)
21. Dopaminergic mechanisms in periaqueductal gray-mediated antinociception.
Tobaldini G; Reis RA; Sardi NF; Lazzarim MK; Tomim DH; Lima MMS; Fischer L
Behav Pharmacol; 2018 Apr; 29(2 and 3-Spec Issue):225-233. PubMed ID: 29035918
[TBL] [Abstract][Full Text] [Related]
22. Non-opioid antinociception produced by brain stem injections of improgan: significance of local, but not cross-regional, cannabinoid mechanisms.
Hough LB; Svokos K; Nalwalk JW
Brain Res; 2009 Jan; 1247():62-70. PubMed ID: 18983834
[TBL] [Abstract][Full Text] [Related]
23. GPR18-NAGly system in periaqueductal gray and chronic neuropathic pain.
Narasimhan M; Mahimainathan L; Reddy PH; Benamar K
Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165974. PubMed ID: 32949767
[No Abstract] [Full Text] [Related]
24. Cannabinoids in the descending pain modulatory circuit: Role in inflammation.
Bouchet CA; Ingram SL
Pharmacol Ther; 2020 May; 209():107495. PubMed ID: 32004514
[TBL] [Abstract][Full Text] [Related]
25. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells.
Chiba T; Ueno S; Obara Y; Nakahata N
J Pharm Pharmacol; 2011 May; 63(5):636-47. PubMed ID: 21492165
[TBL] [Abstract][Full Text] [Related]
26. Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition.
Ho YC; Lee HJ; Tung LW; Liao YY; Fu SY; Teng SF; Liao HT; Mackie K; Chiou LC
J Neurosci; 2011 Oct; 31(41):14600-10. PubMed ID: 21994376
[TBL] [Abstract][Full Text] [Related]
27. Metamizol, a non-opioid analgesic, acts via endocannabinoids in the PAG-RVM axis during inflammation in rats.
Escobar W; Ramirez K; Avila C; Limongi R; Vanegas H; Vazquez E
Eur J Pain; 2012 May; 16(5):676-89. PubMed ID: 22337336
[TBL] [Abstract][Full Text] [Related]
28. Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55.
Henstridge CM; Balenga NA; Kargl J; Andradas C; Brown AJ; Irving A; Sanchez C; Waldhoer M
Mol Endocrinol; 2011 Nov; 25(11):1835-48. PubMed ID: 21964594
[TBL] [Abstract][Full Text] [Related]
29. Antinociception produced by mu opioid receptor activation in the amygdala is partly dependent on activation of mu opioid and neurotensin receptors in the ventral periaqueductal gray.
Tershner SA; Helmstetter FJ
Brain Res; 2000 May; 865(1):17-26. PubMed ID: 10814729
[TBL] [Abstract][Full Text] [Related]
30. The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion.
Kallendrusch S; Kremzow S; Nowicki M; Grabiec U; Winkelmann R; Benz A; Kraft R; Bechmann I; Dehghani F; Koch M
Glia; 2013 Nov; 61(11):1822-31. PubMed ID: 24038453
[TBL] [Abstract][Full Text] [Related]
31. Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats.
Finn DP; Jhaveri MD; Beckett SR; Roe CH; Kendall DA; Marsden CA; Chapman V
Neuropharmacology; 2003 Oct; 45(5):594-604. PubMed ID: 12941373
[TBL] [Abstract][Full Text] [Related]
32. GPR30 receptor promotes preoperative anxiety-induced postoperative hyperalgesia by up-regulating GABA
Jiang M; Sun Y; Lei Y; Hu F; Xia Z; Liu Y; Ma Z; Gu X
BMC Anesthesiol; 2020 Apr; 20(1):93. PubMed ID: 32321426
[TBL] [Abstract][Full Text] [Related]
33. Microinjection of 26RFa, an endogenous ligand for the glutamine RF-amide peptide receptor (QRFP receptor), into the rostral ventromedial medulla (RVM), locus coelureus (LC), and periaqueductal grey (PAG) produces an analgesic effect in rats.
Yoshida K; Nonaka T; Nakamura S; Araki M; Yamamoto T
Peptides; 2019 May; 115():1-7. PubMed ID: 30772446
[TBL] [Abstract][Full Text] [Related]
34. Activation of P2X3 receptors in the cerebrospinal fluid-contacting nucleus neurons reduces formalin-induced pain behavior via PAG in a rat model.
Liu PF; Fang HZ; Yang Y; Zhang QQ; Zhou QQ; Chen SS; Zhou F; Zhang LC
Neuroscience; 2017 Sep; 358():93-102. PubMed ID: 28673711
[TBL] [Abstract][Full Text] [Related]
35. Effects of inflammatory pain on CB1 receptor in the midbrain periaqueductal gray.
Wilson-Poe AR; Wiese B; Kibaly C; Lueptow L; Garcia J; Anand P; Cahill C; Morón JA
Pain Rep; 2021; 6(1):e897. PubMed ID: 33693301
[TBL] [Abstract][Full Text] [Related]
36. Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception.
Wilson AR; Maher L; Morgan MM
Neuropharmacology; 2008 Dec; 55(7):1219-25. PubMed ID: 18723035
[TBL] [Abstract][Full Text] [Related]
37. Oxytocin in the periaqueductal grey regulates nociception in the rat.
Yang J; Li P; Liang JY; Pan YJ; Yan XQ; Yan FL; Hao F; Zhang XY; Zhang J; Qiu PY; Wang DX
Regul Pept; 2011 Aug; 169(1-3):39-42. PubMed ID: 21545817
[TBL] [Abstract][Full Text] [Related]
38. D2 Receptors in the Periaqueductal Gray/Dorsal Raphe Modulate Peripheral Inflammatory Hyperalgesia via the Rostral Ventral Medulla.
Ferrari LF; Pei J; Zickella M; Rey C; Zickella J; Ramirez A; Taylor NE
Neuroscience; 2021 May; 463():159-173. PubMed ID: 33826955
[TBL] [Abstract][Full Text] [Related]
39. Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats.
Datta U; Kelley LK; Middleton JW; Gilpin NW
Psychopharmacology (Berl); 2020 Dec; 237(12):3729-3739. PubMed ID: 32857187
[TBL] [Abstract][Full Text] [Related]
40. The periaqueductal gray and descending pain modulation: why should we study them and what role do they play in chronic pain?
Hemington KS; Coulombe MA
J Neurophysiol; 2015 Oct; 114(4):2080-3. PubMed ID: 25673745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
